Phase 2CompletedAge-related condition
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
A Phase II Randomized, Parallel, Double-blind, Placebo-controlled, Multi-center Clinical Trial of the Efficacy and Safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd. (Industry)
- Enrolment
- 40 enrolled
- Conditions
- Parkinson Disease
- Interventions
- WD-1603 Carbidopa-Levodopa Extended-Release Tablets; Placebo
- Ages
- adults, older adults
- Registry
- NCT05036473
Full record on ClinicalTrials.gov
From the registry
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease. The objective of the study is to access the safety and efficacy of WD-1603 carbidopa-levodopa extended-release tablets in patients with Parkinson's disease.
Primary outcomes
- Changes in the Sum of MDS-UPDRS-II and MDS-UPDRS-III From the Baseline to the 27th Day.
History
Results first posted
Last registry update
Primary completion
Started
Registered